Cathelicidin (LL-37) vs Tachyplesin — mechanism, half-life, dosing, and research status compared. Which is right for your protocol?
LL-37 is the sole human cathelicidin antimicrobial peptide, derived by proteolytic cleavage of the 18 kDa precursor hCAP18 (encoded by the CAMP gene). It is produced by neutrophils, epithelial cells of the skin, gut, and airways, and mast cells....
Calculate Cathelicidin (LL-37) dose →Tachyplesin I is an 18-residue disulfide-bridged beta-hairpin AMP from the hemocytes of the Japanese horseshoe crab (Tachypleus tridentatus). It exhibits potent antimicrobial, antiviral, and antitumor activity....
Calculate Tachyplesin dose →| Parameter | Cathelicidin (LL-37) | Tachyplesin |
|---|---|---|
| Category | Antimicrobial Peptide | Antimicrobial Peptide |
| Research | Clinical Research | Preclinical |
| Half-Life | < 10 min (plasma) | Hours (disulfide stabilized) |
| Typical Dose | Research: 1-100 ug/mL (topical) | N/A |
| Frequency | Varies by application | N/A |
| Route | Endogenous; topical/inhalation (research) | Research only |
| FDA Status | No approval (clinical trials ongoing) | Not approved |
Use ASCEND's free reconstitution calculator to get exact syringe draw amounts for your vial.
For research use only. Not medical advice. ASCEND does not conduct or endorse any specific research protocol. Always consult relevant scientific literature and regulatory guidelines.